Meet our Management

Robert Wessman

CHAIRMAN AND CEO
Portrait of Robert Wessman
Actavis CEO and key strategist 1999 to 2008

Under Wessman‘s leadership Actavis became a leading force in the generic pharmaceutical industry. He changed the company from a small local industry player to the 4th largest global generic company operating in 55 countries.

Alvogen Executive Chairman and CEO 2009-currently

As founder and CEO, Wessman has led Alvogen from being a small US based contract manufacturing business to becoming a top 15 global generics player operating in 35 countries in only six years. Alvogen has received multiple industry recognitions including CPhI Company of the Year Awards and multiple service awards. Development of a balanced yet specialized portfolio consisting of 500 marketed products, as well as a deep pipeline of high-value products in development, is at the core of Wessman’s strategy enabling Alvogen to proactively respond to market needs and fuel sustainable and profitable growth.

Alvotech Founder and Chairman

Alvotech is Biopharmaceutical Company with fully integrated R&D, API and fill and finish capabilities with a brand new state-of-the art facilities. Alvotech has 6 biosimilars in the pipeline with the first product launches scheduled in 2019 at patent expiry.

Operational experience and record growth

Companies led by Wessman have a collective CAGR of more than 60 percent. He has led over 50 strategic acquisitions and partnerships and established operations in over 60 countries around the globe. These companies have achieved very strong organic growth in combination with external growth.

Wessman’s achievements have made him the subject of two Harvard Business School Case Studies, titled “Robert Wessman and the Actavis Winning Formula” (2008) and “Alvogen” (2015).

Alvogen Americas Senior Management

Lisa Graver

President of Alvogen America
Portrait of Lisa Graver

Lisa Graver is the President for the Americas region. Lisa, who joined Alvogen in 2010, has served as EVP of Strategic Operations in the U.S. market for the last three years. In this role she has overseen global R&D and regulatory affairs, portfolio selection, and legal for the U.S.  Under her leadership, Alvogen has built a pipeline 28 potential first-to-file/first-to-market drugs for the U.S. market and a total pipeline of over 60 ANDA‘s. 

Prior to joining Alvogen, Lisa served as Vice President of Intellectual Property for Actavis. She received her JD, cum laude, from Case Western University and Honors Bachelor of Science degree from Lakehead University.



William Hill

EVP – US Commercial Operations
Portrait of William Hill

William Hill brings 25 years of brand and generic pharmaceuticals experience in roles of increasing responsibility that includes multiple therapeutic areas and all classes of trade. Mr. Hill comes to Alvogen from Dr. Reddy’s Laboratories, where he led North American sales and commercial operations.

He was promoted to VP Sales after a successful tenure in National Accounts, highlighted by several Paragraph 4 product launches and Dr. Reddy’s entry into the top ten generic company status. Prior to Dr. Reddy’s, Mr. Hill served in sales and management roles URL, Dey, Warner Chilcott, Endo and Sandoz.

Andrea Johnson

Vice President - Sales Operations
Portrait of Andrea Johnson

Andrea Johnson has more than 20 years of experience in both generic and branded pharmaceuticals. Her knowledge and experience in customer focus, operational effectiveness, teambuilding and process improvements (Kaizen and Lean Six Sigma) allows her to effectively lead and manage Alvogen’s Customer Service, Credit & Collections and Contracting & Pricing operations.

Prior to joining Alvogen, Mrs. Johnson Andrea was the Senior Director of Pricing & Contracts and Financial Sales Operations at Activis Inc., where she was able to successfully led significant operational improvements resulting in millions of dollars in savings.

Mrs. Johnson Andrea has held roles of increasing responsibility throughout her career including successful positions at Johnson & Johnson Healthcare Systems, Pfizer and Alpharma. She has advanced degrees in Education and Mathematics.

Andrea Sweet

Vice President, Legal Affairs
Portrait of Andrea Sweet

As head of Legal for the US, Andrea directs legal strategy for the US business and provides legal guidance to all departments.  She leads Alvogen’s Hatch Waxman litigation strategy and also handles US transactions including acquisitions and partnerships.  Prior to joining Alvogen, Andrea served as Director, Intellectual Property at Actavis.  

She also worked as an Intellectual Property attorney at a boutique law firm.  She received her JD, cum laude, from Western New England University, Bachelors of Arts degrees, cum laude, in Biochemistry/Molecular Biology and Psychology from Boston University and her MBA, with honors, from University of Massachusetts, Amherst.  Andrea has licenses to practice law in New York, New Jersey and Connecticut and is also a registered US Patent Attorney. 

Pat Jaworski

Vice President, US Regulatory Affairs
Portrait of Pat Jaworski

Pat joined Alvogen in January of 2014 bringing with her 35 years of Regulatory experience and FDA interface.   She provides strategic leadership and drives functional value as a subject matter expert, addressing regulatory aspects related to the submission of new ANDAs and commercialization of compliant products.   

Before joining Alvogen, Pat was Vice President of US Generic Regulatory Affairs for Teva Pharmaceuticals, where she executed on functional strategy and long range objectives for Teva’s generic business operations.  Pat also worked for IVAX Pharmaceuticals, where she was Director of US Generic Regulatory Affairs, Par Pharmaceuticals and Lederle Laboratories. 

Vishal Gupta

SENIOR VP - US R&D
Portrait of Vishal Gupta

Vishal joined Alvogen in July 2017 as Senior Vice President of US R&D. In this capacity, he is responsible for all aspects of Generics and Brand R&D. Vishal has extensive industry experience in NDA, 505(b)(2) and ANDA space, most recently as Chief Scientific Officer and SVP, Global Generics R&D at Impax Labs. Prior to that, he was Chief Scientific Officer and SVP, Generics and Brand R&D at CorePharma. He also served in positions of increasing responsibility at Mallinckrodt, Pfizer, and Ranbaxy.

Vishal holds a PhD in Pharmaceutics from The University of Georgia, Athens, GA, USA; an MBA in Strategy and Finance from Washington University, St. Louis, MO, USA; an MS in Pharmaceutics from IIT, Banaras Hindu University, India, and a BS in Pharmacy from Amravati University, India. Vishal is a certified Six Sigma Black Belt and a former Officer of the American Association of Pharmaceutical Scientists. He served as Adjunct Assistant Professor at Midwestern College of Pharmacy, Chicago, IL and St. Louis College of Pharmacy, St. Louis, MO. Vishal is an inventor/co-inventor of several patents, has published peer-reviewed research articles, and has given numerous invited presentations around the world.

Haji Glover

US CFO
Portrait of Haji Glover

Haji Glover, who joined Alvogen in 2012, moved into the US CFO role in May 2017 to oversee US Finance operations.  Prior to this, Haji served as VP of Global Financial Planning & Analysis (FP&A).  During his tenure, Haji has improved all aspects of the monthly financial reporting process, and has successfully established processes vital to Quarterly Forecast submissions and the annual 5 Year Plan.  As VP of FP&A, Haji supported several initiatives set forth by the Group CFO and CEO.  And, interacted with the BOD to ensure proper understanding of the group’s performance.

With over 20 years of experience in Corporate Finance, Haji has also served in several roles with increasing levels of responsibility for Lockheed Martin, Ford Motor Company, and Honeywell International.  He received his MBA, from Binghamton University and Bachelor of Science degree in Finance from Lehigh University.

Richard Harker

VP - COMMERCIALIZATION - INJECTABLES
Portrait of Richard Harker

Richard joined Alvogen in February 2017, to lead Alvogen’s Sales, Marketing, and Commercial Operations for the US Injectables business unit. He brings a wealth of brand and generic injectable pharmaceutical experience spanning more than thirty years.  Most recently, Richard served as VP Sales and Marketing at startup, Claris Lifesciences, helping establish and grow their US business. 

Prior to Claris, Richard held positions of increasing responsibility as Director of Sales and Marketing with at American Regent.  He has extensive experience in sales and sales management, national accounts, and trade relations, and served in roles with Bedford Labs, Ivax, Squibb Diagnostics, and LyphoMed.

Richard holds a Bachelor’s Degree in Business Management from Marshall University.

Entrepreneur Of The Year

Alvogen has been honored by Ernst & Young for rethinking the ways businesses grow and thrive.

ernst&young